These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16595221)

  • 21. Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
    Wang QY; Song Y; Huang W; Xiao L; Wang QS; Feng GM
    Chin Med J (Engl); 2016 Apr; 129(8):883-90. PubMed ID: 27064030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial.
    Kuek S; Wang WJ; Gui SQ
    Zhong Xi Yi Jie He Xue Bao; 2011 Sep; 9(9):965-72. PubMed ID: 21906521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of phlebotomy versus oral contraceptives containing cyproterone acetate on the clinical and biochemical parameters in women with polycystic ovary syndrome: a randomized controlled trial.
    Behboudi-Gandevani S; Abtahi H; Saadat N; Tohidi M; Ramezani Tehrani F
    J Ovarian Res; 2019 Aug; 12(1):78. PubMed ID: 31470879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
    Sahu A; Tripathy P; Mohanty J; Nagy A
    J Gynecol Obstet Hum Reprod; 2019 May; 48(5):335-339. PubMed ID: 30316907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial.
    Amiri M; Nahidi F; Bidhendi-Yarandi R; Khalili D; Tohidi M; Ramezani Tehrani F
    Hum Reprod; 2020 Jan; 35(1):175-186. PubMed ID: 31916574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
    Orbetsova M; Kamenov Z; Kolarov G; Zakharieva S; Khristov V; Atanasova I; Shigarminova R; Milcheva B; Genchev G
    Akush Ginekol (Sofiia); 2006; 45(7):16-28. PubMed ID: 17489164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
    Vartiainen M; de Gezelle H; Broekmeulen CJ
    Eur J Contracept Reprod Health Care; 2001 Mar; 6(1):46-53. PubMed ID: 11334476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome.
    Sabuncu T; Harma M; Harma M; Nazligul Y; Kilic F
    Fertil Steril; 2003 Nov; 80(5):1199-204. PubMed ID: 14607575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up.
    Yildizhan R; Gokce AI; Yildizhan B; Cim N
    Gynecol Endocrinol; 2015 May; 31(5):396-400. PubMed ID: 25739031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism.
    De Leo V; Fruzzetti F; Musacchio MC; Scolaro V; Di Sabatino A; Morgante G
    Contraception; 2013 Sep; 88(3):364-8. PubMed ID: 23769016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
    Puurunen J; Piltonen T; Puukka K; Ruokonen A; Savolainen MJ; Bloigu R; Morin-Papunen L; Tapanainen JS
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4798-807. PubMed ID: 24152688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Trpković D; Balint-Perić L
    Gynecol Endocrinol; 1990 Sep; 4(3):157-68. PubMed ID: 2284980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
    Armstrong VL; Wiggam MI; Ennis CN; Sheridan B; Traub AI; Atkinson AB; Bell PM
    QJM; 2001 Jan; 94(1):31-7. PubMed ID: 11161134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins.
    Amiri M; Ramezani Tehrani F; Nahidi F; Kabir A; Azizi F; Carmina E
    Metabolism; 2017 Aug; 73():22-35. PubMed ID: 28732568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome.
    Chung JP; Yiu AK; Chung TK; Chan SS
    J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):166-71. PubMed ID: 24656700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
    Erenus M; Yücelten D; Gürbüz O; Durmuşoğlu F; Pekin S
    Fertil Steril; 1996 Aug; 66(2):216-9. PubMed ID: 8690104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.